{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=recombinant+viral+vaccine+therapy",
    "query": {
      "intervention": "recombinant viral vaccine therapy"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 189,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=recombinant+viral+vaccine+therapy&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T23:47:31.069Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00426712",
      "title": "Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "1018 ISS immunostimulatory oligonucleotide with HBV surface antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis B Vaccine (Recombinant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Dynavax Technologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2006-01",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2019-03-20",
      "last_synced_at": "2026-10-01T23:47:31.069Z",
      "location_count": 4,
      "location_summary": "Costa Mesa, California • Brooklyn Center, Minnesota • Austin, Texas + 1 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Brooklyn Center",
          "state": "Minnesota"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00426712"
    },
    {
      "nct_id": "NCT00604175",
      "title": "Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections",
        "Sexually Transmitted Diseases"
      ],
      "interventions": [
        {
          "name": "Quadrivalent HPV vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "13 Years to 45 Years · Female only"
      },
      "enrollment_count": 319,
      "start_date": "2008-02",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-10-01T23:47:31.069Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Alhambra, California • La Jolla, California + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00604175"
    },
    {
      "nct_id": "NCT00000746",
      "title": "A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "rgp120/HIV-1 SF-2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Env 2-3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HIVAC-1e",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gp160 Vaccine (MicroGeneSys)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 56,
      "start_date": null,
      "completion_date": "1994-07",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-10-01T23:47:31.069Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000746"
    },
    {
      "nct_id": "NCT04283461",
      "title": "Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19",
        "COVID-19 Immunisation"
      ],
      "interventions": [
        {
          "name": "mRNA-1273",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 120,
      "start_date": "2020-03-16",
      "completion_date": "2022-04-26",
      "has_results": true,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-10-01T23:47:31.069Z",
      "location_count": 3,
      "location_summary": "Decatur, Georgia • Bethesda, Maryland • Seattle, Washington",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04283461"
    },
    {
      "nct_id": "NCT03969641",
      "title": "Safety of RIV4 Versus IIV4 in Pregnant Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Safety",
        "Adverse Event Following Immunisation",
        "Birth Outcomes"
      ],
      "interventions": [
        {
          "name": "Quadrivalent Recombinant Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 384,
      "start_date": "2019-09-05",
      "completion_date": "2021-09-29",
      "has_results": true,
      "last_update_posted_date": "2023-01-11",
      "last_synced_at": "2026-10-01T23:47:31.069Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Durham, North Carolina • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03969641"
    },
    {
      "nct_id": "NCT00001043",
      "title": "A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections",
        "HIV Seronegativity"
      ],
      "interventions": [
        {
          "name": "gp160 Vaccine (Immuno-AG)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 20,
      "start_date": null,
      "completion_date": "1997-05",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-10-01T23:47:31.069Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Seattle, Washington",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001043"
    },
    {
      "nct_id": "NCT00539864",
      "title": "Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "FluBlok Influenza Vaccination",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TIV (Fluzone) Influenza Vaccination",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Protein Sciences Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "50 Years to 64 Years"
      },
      "enrollment_count": 602,
      "start_date": "2007-09",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2011-07-27",
      "last_synced_at": "2026-10-01T23:47:31.069Z",
      "location_count": 5,
      "location_summary": "Fresno, California • Hayward, California • Roseville, California + 2 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Hayward",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00539864"
    },
    {
      "nct_id": "NCT00727636",
      "title": "Immunogenicity to Human Papillomavirus Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Inflammatory Bowel Disease"
      ],
      "interventions": [
        {
          "name": "Gardasil vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "26 Years",
        "sex": "FEMALE",
        "summary": "9 Years to 26 Years · Female only"
      },
      "enrollment_count": 53,
      "start_date": "2008-07",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2011-05-27",
      "last_synced_at": "2026-10-01T23:47:31.069Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00727636"
    },
    {
      "nct_id": "NCT04398706",
      "title": "Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pneumococcal Immunisation",
        "Diphtheria Immunisation",
        "Tetanus Immunisation",
        "Pertussis Immunisation",
        "Hepatitis B Immunisation",
        "Haemophilus Influenzae Type b Immunisation",
        "Polio Immunisation",
        "Measles Immunisation",
        "Rubella Immunisation",
        "Varicella Immunisation",
        "Mumps Immunisation"
      ],
      "interventions": [
        {
          "name": "Pneumococcal Conjugate Vaccine formulation 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal Conjugate Vaccine formulation 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal Conjugate Vaccine formulation 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varicella Virus Vaccine Live",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Measles, Mumps, and Rubella Virus Vaccine Live",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotavirus Vaccine, Live, Oral, Pentavalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis B Vaccine* [Recombinant] *as applicable",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "15 Months",
        "sex": "ALL",
        "summary": "42 Days to 15 Months"
      },
      "enrollment_count": 852,
      "start_date": "2020-05-22",
      "completion_date": "2023-08-10",
      "has_results": true,
      "last_update_posted_date": "2025-09-08",
      "last_synced_at": "2026-10-01T23:47:31.069Z",
      "location_count": 49,
      "location_summary": "Jonesboro, Arkansas • Bellflower, California • Huntington Park, California + 41 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04398706"
    },
    {
      "nct_id": "NCT02600585",
      "title": "Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Human Influenza"
      ],
      "interventions": [
        {
          "name": "Recombinant Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Protein Sciences Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 254648,
      "start_date": "2015-11",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2017-10-12",
      "last_synced_at": "2026-10-01T23:47:31.069Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02600585"
    }
  ]
}